The report said that precisely this treatment option will serve as an option for patients who refuse to operate.
Before and after the injury is treated with medicine. Photo: Journal of the American Academy of Dermatology.
Supports the benefit of a range of cases published in the literature sirolimusClassically known as rapamycin, in patients with sebaceous nevus (NS) and epidermal nevus (EN).
This drug acts as a selective immunosuppressive agent that inhibits the activation of T cells induced by various stimuli. The report states that precisely this treatment option will serve as an alternative for patients who refuse surgery or are said to have interventions that represent some deformity of the injured area.
NS is a sporadic lesion that is not inherited from either parent or caused by an infection. It is caused by a mutation in a gene called HRAS that affects only the skin in that area and occurs during fetal development.
EN, meanwhile, is a non-cancerous (benign) dark patch of skin caused by overgrowth of skin cells. They are present at birth or develop in childhood. They may look like flat, or slightly raised, velvety blisters (papules).
In the case series, patients aged 18, 15, 12 and 11 years were evaluated who received the said treatment and presented improvement by the first month of drug application.
sirolimus The topical is not readily absorbed into the skin and has a favorable safety profile, with no systemic adverse effects. Similarly, it has been used to treat conditions such as angiofibromas, lymphatic malignancies, as described among other conditions.
However, the authors of the publication support the need for additional studies to further evaluate the effectiveness of this drug in these patients.
Access the document here.
